Summary
Trans Detransition: What the Data Shows. Research into trans detransition rates in North West Europe.
Trans Detransition: What the Data Shows
The anti-trans movement frequently cites detransition as a reason to oppose gender-affirming healthcare.
Online, images often depict trans men post-double mastectomy, accompanied by claims of regret. There is little attention on trans women, as this does not fit the trans hostile narrative that young women are swept up in a so-called “social contagion” of “gender ideology” – a term originally adopted by the Vatican in the late 1990s to oppose women’s equality and now repurposed to dehumanise trans people.
A central figure in this area of gender-critical debate has been Keira Bell, a detransitioner, who has very strong links with the gender-critical movement and, by association, the evangelical far-right that largely fund the culture war against trans people – with additional funding support from trans hostile figures such as J.K. Rowling.
In reality, detransition is remarkably rare, though reliable statistics can be difficult to find. However, TransLucent is recognised for its data-driven research; this report presents our findings, with references provided at the bottom of this post.
- Trans detransition: What the Data Shows – Key Findings
Across Europe, actual data shows that detransition or regret rates for gender-affirming care are very low, usually between 0.3% and 1%. Most European countries don’t measure detransition at all, likely because it is so rare. In the UK, the only published statistic is 0.5%, based on national clinic records.
In public debate, detransition is often misrepresented. Taking a break from treatment, changing legal gender, or leaving a clinic are commonly (and incorrectly) described as detransition. The rarest form of detransition is when someone regrets their identity, and even this occurs in fewer than 1% of long-term studies.
Most of the time, people pause or reverse their transition because of outside pressures like family rejection, discrimination, job loss, or concerns for their safety. In fact, gender-affirming care has lower regret rates than almost any other major medical procedure, including hip or knee replacements and cosmetic surgery.
There is no European data to back up claims of high regret or a sudden increase in detransition. The UK could run a comprehensive long-term study but hasn’t so far. Policy debates often rely on data from countries that don’t publish detransition numbers at all, creating a misleading sense of evidence.
- Why Detransition Is Misunderstood
Detransition is the single most misquoted statistic in UK debates. The media and politicians often cite numbers without providing any source, definition, or context. As we’ve noted before: “Numbers appear in newspaper columns and parliamentary contributions with no source, no country, and no definition attached.”
There are three main reasons for this confusion:
- Misdefinition: Taking a break from hormones, changing legal documents, or losing contact with a clinic does not count as detransition.
- Misattribution: When someone pauses care because of outside pressure, it’s usually mistaken for changing their identity.
- Misuse of missing data: Countries without detransition numbers are often cited to support claims of high regret, even though no data exist.
This all leads to a public conversation that is out of touch with the real, published evidence.
- What Detransition Is (And Is Not)
Just stopping treatment isn’t the same as detransition. People might pause hormone therapy because of cost, moving house, supply issues, illness, pregnancy, or paperwork delays.
Losing contact with a patient isn’t the same as regret. In medicine generally, if someone stops attending appointments, it’s not considered a treatment failure. However, in the detransition debate, these people are often wrongly counted.
Most of the time, people pause care because of outside pressures. Research (Turban et al., 2021) shows that over 80% of people who pause care do it for outside reasons, not because they’ve changed their mind about their identity. However, because this study surveyed currently identifying transgender people, it may undercount those who fully detransitioned and disengaged from trans community spaces.
However, as we’ve said before: “A person forced to detransition by transphobia has not concluded their care was wrong.” Changing your legal gender marker is just an administrative thing – usually about paperwork, safety, or work issues. It doesn’t mean someone regrets surgery or hormones. Actually, changing identity is rare. Long-term data from Europe shows that this kind of regret is below 2%.
- Trans Detransition – What the Evidence Shows
Looking at the numbers across Europe, detransition and regret rates are always between 0.3% and 1-2%. For example:
- United Kingdom: 0.5%
- Netherlands: 0.6% for trans women and 0.3% for trans men
- Sweden: 0.3% (for changes in legal status, not medical outcomes)
No study shows high regret, an increase over time, or any surge in detransition.
- Country-by-Country Evidence
United Kingdom — 0.5%
A study at a national gender clinic examined 3,398 patients (2016–2017) and found only 16 cases of detransition or regret (0.47%). Of those, 12 said it was because of social pressure. Only 3 out of 3,398 (less than 0.1%) detransitioned without planning to transition again.
UK Clarity caveat: This figure comes from a 2019 conference abstract, based on a short (roughly one-year) review of clinical notes; it has never been peer-reviewed, and this methodology is likely to miss cases, since regret and detransition can emerge many years after care ends. No UK study to date has followed patients for long enough to produce a reliable long-term rate, which is exactly why we’re calling for the 15-year national study set out below
Netherlands — 0.6% and 0.3%
A long-term study from Amsterdam (1972–2015) found regret rates of 0.6% for trans women and 0.3% for trans men after surgery. It took an average of 11 years for people to express regret, so that short-term studies might miss some cases.
A larger review of 27 studies (almost 8,000 people) reported an overall rate of surgical regret of about 1%. Young people who start puberty blockers almost always continue transition: one study found 98% went on to take gender-affirming hormones.
Sweden — 0.3% (legal, not clinical)
A study of 7,293 adults with gender dysphoria found 2,467 changed legal gender, and only 21 reversed it (0.3% of everyone, or 0.9% of those who changed). After 10 years, nearly 98% had kept their legal gender change. This data only measures legal status, not medical regret.
- What the Evidence Does Not Show
There’s simply no evidence for high regret. No European studies show widespread misdiagnosis. There’s also no sign that detransition rates are rising- long-term data shows these rates stay steady over time. Detransition doesn’t mean someone was misdiagnosed. Most pauses in care occur due to external pressure. Changing your legal gender back doesn’t mean you regret medical treatment; it’s just an administrative move.
- Structural Data Failures
Most countries don’t even measure detransition, presumably because they don’t consider the data important, since detransition is quite rare.
Out of nine European countries commonly compared, six don’t publish any detransition data. In many health systems, detransition isn’t a clinical category, so there’s no diagnostic code and no easy way to track it.
Studies that don’t follow people for long enough also miss cases of regret, since regret can happen 8–15 years after care. Youth studies with less than five years of follow-up can’t track long-term regret. And importantly, detransition rates only count people who actually got medical transition—not all trans people. Critics often mix up these groups to exaggerate the numbers.
- How Gender-Affirming Care Compares
Regret rates for gender-affirming care are much lower than for most other medical treatments:
- Knee replacements: 10–20% of people are dissatisfied
- Hip replacements: 5–10% have regrets
- Cosmetic surgery: 5–15% regret
- Gender-affirming care: just 0.3–1%
By any measure, gender-affirming care is one of the most stable and least regretted procedures in medicine today.
- What This Means for UK Policy
The only official detransition rate in the UK is 0.5%. In her review, Hillary Cass found fewer than ten people who detransition. However, her review noted that total UK rates remain difficult to quantify because NHS gender services do not systematically track patients long-term after they leave care.
If a trans hostile source claims a higher number, they should provide a proper source, a country, the total number of patients, a follow-up period, and a citation—almost none of the claims in “the debate” provide these.
The UK still hasn’t done a national long-term study, even though it has some of the best health data in Europe. This lack of data lets myths and guesses shape policy, especially when people cite countries that don’t even publish detransition numbers. Putting restrictions in place without real evidence isn’t the answer. If we’re uncertain, we need better measurement—not more barriers.
- What Needs to Happen Next
- The UK should carry out a national 15-year study that tracks people over time, so we finally have the long-term data that’s missing from the global research.
- We need a clear, consistent definition of detransition that works across clinics and government systems.
- NHS England should create a specific code for detransition, so it’s possible to track these cases routinely like any other health outcome.
- And finally, the government, regulators, and NHS should share the real evidence: detransition is rare, regret is even rarer, outside pressures drive most pauses in care, and gender-affirming care has some of the lowest regret rates in all of medicine.
Trans Detransition: What the Data Shows (References)
- Stonewall. “Dispelling myths around detransition”, 2019.
- Davies S, McIntyre S, Rypma C. EPATH Conference Abstract, 2019.
- Expósito-Campos P, et al. PMC, 2024.
- Wiepjes CM, et al. Journal of Sexual Medicine, 2018.
- van der Loos MATC, et al. Lancet Child & Adolescent Health, 2022.
- Bustos VP, et al. Plastic and Reconstructive Surgery – Global Open, 2021.
- Gezondheidsraad (Dutch Health Council), 2026.
- Clark KD, et al. JAMA Network Open, 2025.
- Deutscher Bundestag, WD 8-019-26.
- Haute Autorité de Santé, 2025.
- Vidart A., Clinical Presentation, 2024.
- Glintborg D, et al. Transgender Health, 2025.
- Stephensen Ó., MPH Thesis, University of Iceland, 2024.
- Bolstad S-H, et al. BMC Public Health, 2025.
- Socialstyrelsen, Sweden Guidelines, 2026.
- COHERE Finland (PALKO), 2020.
- Turban JL, et al. LGBT Health, 2021.
Trans Detransition: What the Data Shows
